Anatomy and Physiology of Limbic System Dysfunction in Parkinson's Disease

Parkinson's Disease: Non-Motor and Non-Dopaminergic Features

Volumn , Issue , 2011, Pages 71-78

  Grace, Anthony A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Addiction; Depression; Dopamine; Impulse control disorders; Limbic system dysfunction; Mesolimbic; Parkinson's disease; Psychosis; Sensitization

Indexed keywords

EID: 84885493303     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444397970.ch6     Document Type: Chapter

References (103)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) in the central nervous system and its relation to the Parkinson syndrome in man. DtschMedWochenschr 1962;87:1807-10 (in German).
2. Grace AA, Bunney BS. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons - 1. Identification and characterization. Neuroscience 1983;10(2):301-15.
3. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 1984;4(11):2866-76.
4. Grace AA, Onn SP. Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J Neurosci 1989;9(10):3463-81.
5. Grace AA, Bunney BS. Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity. Brain Res 1985;333(2):271-84.
6. Floresco SB, Todd CL, Grace AA. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J Neurosci 2001;21(13):4915-22.
7. Floresco SB, West AR, Ash B, et al. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003;6(9):968-73.
8. Lodge DJ, Grace AA. The hippocampus modulates dopamine neuron responsivity by regulating the intensity of phasic neuron activation. Neuropsychopharmacology 2006;31:1356-61.
9. Bunney BS, Grace AA. Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 1978;23(16):1715-27.
10. Hollerman JR, Grace AA. The effects of dopamine-depleting brain lesions on the electrophysiological activity of rat substantia nigra dopamine neurons. Brain Res 1990;533(2):203-12.
11. Hollerman JR, Abercrombie ED, Grace AA. Electrophysiological, biochemical, and behavioral studies of acute haloperidolinduced depolarization block of nigral dopamine neurons. Neuroscience 1992;47(3):589-601.
12. Hollerman JR, Grace AA. Acute haloperidol administration induces depolarization block of nigral dopamine neurons in rats after partial dopamine lesions. Neurosci Lett 1989;96(1):82-8.
13. Harden DG, Grace AA. Activation of dopamine cell firing by repeated l-DOPA administration to dopamine-depleted rats: its potential role in mediating the therapeutic response to l-DOPA treatment. J Neurosci 1995;15(9):6157-66.
14. Segal DS, Mandell AJ. Long-term administration of damphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav 1974;2(2):249-55.
15. Post RM, Rose H. Increasing effects of repetitive cocaine administration in the rat. Nature 1976;260(5553):731-2.
16. Lodge DJ, Grace AA. Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. J Neurosci 2008;28(31):7876-82.
17. Grace AA. Gating of information flow within the limbic system and the pathophysiology of schizophrenia. Brain Res Brain Res Rev 2000;31(2-3):330-41.
18. Merims D, Giladi N. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Rel Disord 2008;14(4):273-80.
19. Fasano A, Elia AE, Soleti F, et al. Punding and computer addiction in Parkinson's disease. Mov Disord 2006;21(8):1217-8.
20. Spigset O, von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997;17(5):1027-30.
21. Freeman AS, Meltzer LT, Bunney BS. Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci 1985;36(20):1983-94.
22. Schultz W. The phasic reward signal of primate dopamine neurons. Adv Pharmacol 1998;42:686-90.
23. Grace AA, Bunney BS. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 1984;4(11):2877-90.
24. Charlety PJ, Grenhoff J, Chergui K, et al. Burst firing of mesencephalic dopamine neuronsis inhibited by somatodendritic application of kynurenate. Acta Physiol Scand 1991;142:105-12.
25. Suaud-Chagny MF, Chergui K, Chouvet G, Gonon F. Relationship between dopamine release in the rat nucleus accumbens and the discharge activity of dopaminergic neurons during local in vivo application of amino acids in the ventral tegmental area. Neuroscience 1992;49(1):63-72.
26. Smith ID, Grace AA. Role of the subthalamic nucleus in the regulation of nigral dopamine neuron activity. Synapse 1992;12(4):287-303.
27. West AR, Grace AA. Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis. J Neurosci 2002;22(1):294-304.
28. Zigmond MJ, Berger TW, Grace AA, Stricker EM. Compensatory responses to nigrostriatal bundle injury. Studies with 6-hydroxydopamine in an animalmodel of parkinsonism. Mol Chem Neuropathol 1989;10(3):185-200.
29. Stachowiak MK, Bruno JP, Snyder AM, et al. Apparent sprouting of striatal serotonergic terminals after dopaminedepleting brain lesions in neonatal rats. Brain Res 1984;291(1): 164-7.
30. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia- thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85:119-46.
31. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-81.
32. Gross RE, Lozano AM, Lang AE, et al. The effects of pallidotomy on Parkinson's disease: study design and assessment techniques. Acta Neurochir 1997;68:24-8.
33. Schuurman PR, de Bie RM, Speelman JD, Bosch DA. Bilateral posteroventral pallidotomy in advanced Parkinson's disease in three patients. Mov Disord 1997;12(5):752-5.
34. O'Donnell P, Grace AA. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J Neurosci 1995;15(5 Pt 1):3622-39.
35. McGinty VB, Grace AA. Timing-dependent regulation of evoked spiking in nucleus accumbens neurons by integration of limbic and prefrontal cortical inputs. J Neurophysiol 2009;101(4):1823-35.
36. Jarrard LE. What does the hippocampus really do? Behav Brain Res 1995;71:1-10.
37. Maren S. Neurotoxic or electrolytic lesions of the ventral subiculum produce deficits in the acquisition and expression of Pavlovian fear conditioning in rats. Behav Neurosci 1999;113(2):283-90.
38. Sharp PE. Complimentary roles for hippocampal versus subicular/entorhinal place cells in coding place, context, and events. Hippocampus 1999;9(4):432-43.
39. Fanselow MS. Contextual fear, gestalt memories, and the hippocampus. Behav Brain Res 2000;110(1-2):73-81.
40. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007;30(5):220-7.
41. Ragozzino ME. The contribution of the medial prefrontal cortex, orbitofrontal cortex, and dorsomedial striatum to behavioral flexibility. Ann N Y Acad Sci 2007;1121:355-75.
42. O'Donnell P, Grace AA. Tonic D2-mediated attenuation of cortical excitation in nucleus accumbens neurons recorded in vitro. Brain Res 1994;634(1):105-12.
43. Goto Y, Grace AA. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 2005;8:805-12.
44. Goto Y, Grace AA. Limbic and cortical information processing in the nucleus accumbens. Trends Neurosci 2008;31(11):552-8.
45. Hollerman JR, Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci 1998;1(4):304-9.
46. Conrad KL, Tseng KY, Uejima JL, et al. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 2008;454(7200):118-21.
47. Goto Y, Grace AA. Dopamine-dependent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 2005;47(2):255-66.
48. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992;115(Pt 6):1727-51.
49. Morrison CE, Borod JC, Brin MF, et al. Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MSPD). J Neural Transm 2004;111(10-11):1333-41.
50. Post R.M. Intermittent versus continuous stimulation: effect of time interval on the development of sensitization or tolerance. Life Sci 1980;26(16):1275-82.
51. Mehta MA, Manes FF, Magnolfi G, et al. Impaired set-shifting and dissociable effects on tests of spatial working memory following the dopamine D2 receptor antagonist sulpiride in human volunteers. Psychopharmacology 2004;176(3-4):331-42.
52. Roberts AC, De Salvia MA, Wilkinson LS, et al. 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of theWisconsin Card Sort Test: possible interactions with subcortical dopamine. J Neurosci 1994;14(5 Pt 1):2531-44.
53. Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson's disease. Brain 2001;124(Pt 12):2503-12.
54. Cools R, Lewis SJG, Clark L, et al.. l-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007;32:180-9.
55. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A communitybased study. Arch Neurol 1996;53(2):175-9.
56. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54(3):363-75.
57. Veazey C, Aki SO, Cook KF, et al. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005;17(3):310-23.
58. Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 2006;248(1-2): 266-70.
59. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999;14(9):711-8.
60. Kuopio AM, Marttila RJ, Helenius H, et al. The quality of life in Parkinson's disease. Mov Disord 2000;15(2):216-23.
61. Schrag A, Jahanshahi M, Quinn NP. What contributes to depression in Parkinson's disease?. Psychol Med 2001;31(1): 65-73.
62. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15(4):669-77.
63. Menza MA, Mark MH. Parkinson's disease and depression: the relationship to disability and personality. J Neuropsychiatry Clin Neurosci 1994;6(2):165-9.
64. Manaye KF, Sonsalla PK, Barnett G, et al. 1-Methyl-4- (2-methylphenyl)-1,2,3,6-tetrahydropyridine (2CH3-MPTP)- induced degeneration of mesostriatal dopaminergic neurons in the mouse: biochemical and neuroanatomical studies. Brain Res 1989;491(2):307-15.
65. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993;91(2-3):75-109.
66. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988;45(5):497-501.
67. Carey RJ. An examination of parkinsonian versus anhedonia contributions to self-stimulation impairments induced by dopamine dysfunction. Behav Brain Res 1986;22(2):117-25.
68. Huang AC, Hsiao S. Haloperidol attenuates rewarding and aversively conditioned suppression of saccharin solution intake: reevaluation of the anhedonia hypothesis of dopamine blocking. Behav Neurosci 2002;116(4):646-50.
69. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318(1):121-34.
70. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55(3):296-300.
71. LemkeMR. Dopamine agonists in the treatment of non-motor symptoms of Parkinson's disease: depression. Eur J Neurol 2008;15(Suppl 2):9-14.
72. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303(2):791-804.
73. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990;347(6289):146-51.
74. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003;10(4):399-406.
75. Menza MA, Golbe LI, Cody RA, Forman NE. Dopaminerelated personality traits in Parkinson's disease. Neurology 1993;43(3 Pt 1):505-8.
76. Fujii C, Harada S, Ohkoshi N, et al. Cross-cultural traits for personality of patients with Parkinson's disease in Japan. Am J Med Genet 2000;96(1):1-3.
77. Zuckerman M, Kuhlman DM. Personality and risk-taking: common biosocial factors. J Personality 2000;68(6):999-1029.
78. Comings DE, Gonzalez N, Wu S, et al. Studies of the 48 bp repeat polymorphism of the DRD4 gene in impulsive, compulsive, addictive behaviors: Tourette syndrome, ADHD, pathological gambling, and substance abuse. Am J Med Genet 1999;88(4):358-68.
79. Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114(Pt 5):2095-122.
80. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65(8):1239-45.
81. Weinberger DR. A connectionist approach to the prefrontal cortex. J Neuropsychiatry Clin Neurosci 1993;5(3):241-53.
82. Goldman-Rakic PS. The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Philos Trans R Soc Lond B Biol Sci 1996;351(1346): 1445-53.
83. Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol 1999;56(5):595-601.
84. Giladi N, Treves TA, Paleacu D, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm 2000;107(1):59-71.
85. Friedman A, Sienkiewicz J. Psychotic complications of longterm levodopa treatment of Parkinson's disease. Acta Neurol Scand 1991;84(2):111-3.
86. Koller WC, Glatt SL, Hubble JP, et al. Apolipoprotein E genotypes in Parkinson's disease with and without dementia. Ann Neurol 1995;37(2):242-5.
87. Weintraub D. Dopamine and impulse-control disorders in Parkinson's disease. Ann Neurol 2008;64(Suppl 2):S93-100.
88. Avanzi M, Baratti M, Cabrini S, et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006;21(12):2068-72.
89. Giladi N, Weitzman N, Schreiber S, et al. New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007;21(5):501-6.
90. Dodd ML, Klos KJ, Bower JH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62(9):1377-81.
91. Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003;61(3):422-3.
92. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse-control disorders in Parkinson disease. Arch Neurol 2006;63(7):969-73.
93. O'Doherty J, Kringelbach ML, Rolls ET, et al. Abstract reward and punishment representations in the human orbitofrontal cortex. Nat Neurosci 2001;4(1):95-102.
94. Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003;160(11): 1990-4.
95. Bechara A, Tranel D, Damasio H. Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 2000;123(Pt 11):2189-202.
96. Fiorino DF, Coury A, Fibiger HC, Phillips AG. Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav Brain Res 1993;55(2):131-41.
97. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend 1998;51(1-2): 13-22.
98. Koob GF. Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 1992;654:171-91.
99. Baldo BA, Jain K, Veraldi L, et al. A dopamine D1 agonist elevates self-stimulation thresholds: comparison to other dopamine-selective drugs. Pharmacol Biochem Behav 1999; 62(4):659-72.
100. Volkow ND, Wang GJ, Fowler JS, et al. Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D2 receptor levels. Am J Psychiatry 1999;156(9): 1440-3.
101. Dalley JW, Fryer TD, Brichard L, et al. Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement. Science 2007;315(5816):1267-70.
102. LeDoux JE. Emotion circuits in the brain. Annu Rev Neurosci 2000;23:155-84.
103. Rosenkranz JA, Grace AA. Dopamine-mediated modulation of odour-evoked amygdala potentials during pavlovian conditioning. Nature 2002;417(6886):282-7.